000166506 001__ 166506
000166506 005__ 20240229133522.0
000166506 0247_ $$2doi$$a10.1093/neuonc/noaa276
000166506 0247_ $$2pmid$$apmid:33331885
000166506 0247_ $$2ISSN$$a1522-8517
000166506 0247_ $$2ISSN$$a1523-5866
000166506 0247_ $$2altmetric$$aaltmetric:96266577
000166506 037__ $$aDKFZ-2020-02949
000166506 041__ $$aeng
000166506 082__ $$a610
000166506 1001_ $$aAdolph, Jonas E$$b0
000166506 245__ $$aLocal and Systemic Therapy of Recurrent Ependymoma in Children and Adolescents: Short- and Long-term Results of the E-HIT-REZ 2005 Study.
000166506 260__ $$aOxford$$bOxford Univ. Press$$c2021
000166506 3367_ $$2DRIVER$$aarticle
000166506 3367_ $$2DataCite$$aOutput Types/Journal article
000166506 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1626177562_32275
000166506 3367_ $$2BibTeX$$aARTICLE
000166506 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000166506 3367_ $$00$$2EndNote$$aJournal Article
000166506 500__ $$a2021 Jun 1;23(6):1012-1023
000166506 520__ $$aSurvival in recurrent ependymomas in children and adolescents mainly depends on the extent of resection. Studies on repeated radiotherapy and chemotherapy at relapse have shown conflicting results.Using data from the German multi-center E-HIT-REZ-2005 study, we examined the role of local therapy and the efficacy of chemotherapy with blockwise temozolomide (TMZ) in children and adolescents with recurrent ependymomas.53 patients with a median age of 6.9 years (1.25-25.4) at 1 st recurrence and a median follow-up time of 36 months (2-115) were recruited. Gross and near total resection (GTR/NTR) were achieved in 34 (64.2%) patients and associated with a markedly improved 5-year overall survival (OS) of 48.7% vs. 5.3% in less than GTR/NTR. Radiotherapy showed no improvement in OS following complete resection (OS: 70 (CI: 19.9-120.1) vs. 95 (CI: 20.7-169.4) months), but an advantage was found in less than GTR/NTR (OS: 22 (CI: 12.7-31.3) vs. 7 (CI: 0-15.8) months). Following application of TMZ, disease progression was observed in most evaluable cases (18/21). Subsequent change to oral etoposide and trofosfamide showed no improved response. PF-A EPN were most abundant in relapses (n = 27). RELA-positive EPN (n=5) had a 5-year-OS of 0%.The extent of resection is the most important predictor of survival at relapse. Focal re-irradiation is a useful approach if complete resection cannot be achieved, but no additional benefit was seen after GTR/NTR. Longer-term disease stabilization (>6 months) mediated by TMZ occurred in a small number of cases (14.3%).
000166506 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000166506 588__ $$aDataset connected to CrossRef, PubMed,
000166506 650_7 $$2Other$$achemotherapy
000166506 650_7 $$2Other$$aependymoma
000166506 650_7 $$2Other$$aradiotherapy
000166506 650_7 $$2Other$$arelapse
000166506 650_7 $$2Other$$atumor resection
000166506 7001_ $$aFleischhack, Gudrun$$b1
000166506 7001_ $$aMikasch, Ruth$$b2
000166506 7001_ $$aZeller, Julia$$b3
000166506 7001_ $$aWarmuth-Metz, Monika$$b4
000166506 7001_ $$aBison, Brigitte$$b5
000166506 7001_ $$aMynarek, Martin$$b6
000166506 7001_ $$aRutkowski, Stefan$$b7
000166506 7001_ $$aSchüller, Ulrich$$b8
000166506 7001_ $$avon Hoff, Katja$$b9
000166506 7001_ $$aObrecht, Denise$$b10
000166506 7001_ $$aPietsch, Torsten$$b11
000166506 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan M$$b12$$udkfz
000166506 7001_ $$0P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aPajtler, Kristian W$$b13$$udkfz
000166506 7001_ $$0P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aWitt, Olaf$$b14$$udkfz
000166506 7001_ $$0P:(DE-He78)046fd145f1008f83f6236580727bbc0f$$aWitt, Hendrik$$b15$$udkfz
000166506 7001_ $$aKortmann, Rolf-Dieter$$b16
000166506 7001_ $$aTimmermann, Beate$$b17
000166506 7001_ $$aKrauß, Jürgen$$b18
000166506 7001_ $$aFrühwald, Michael C$$b19
000166506 7001_ $$aFaldum, Andreas$$b20
000166506 7001_ $$aKwiecien, Robert$$b21
000166506 7001_ $$aBode, Udo$$b22
000166506 7001_ $$aTippelt, Stephan$$b23
000166506 7001_ $$aHIT-Network, German GPOH$$b24$$eCollaboration Author
000166506 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noaa276$$gp. noaa276$$n6$$p1012-1023$$tNeuro-Oncology$$v23$$x1523-5866$$y2021
000166506 909CO $$ooai:inrepo02.dkfz.de:166506$$pVDB
000166506 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000166506 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000166506 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000166506 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)046fd145f1008f83f6236580727bbc0f$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000166506 9130_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000166506 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000166506 9141_ $$y2021
000166506 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2020-08-32$$wger
000166506 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-08-32
000166506 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-08-32
000166506 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-08-32
000166506 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-08-32
000166506 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-08-32
000166506 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-08-32
000166506 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-08-32
000166506 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-08-32
000166506 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2018$$d2020-08-32
000166506 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bNEURO-ONCOLOGY : 2018$$d2020-08-32
000166506 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000166506 9201_ $$0I:(DE-He78)B310-20160331$$kB310$$lKKE Pädiatrische Onkologie$$x1
000166506 980__ $$ajournal
000166506 980__ $$aVDB
000166506 980__ $$aI:(DE-He78)B062-20160331
000166506 980__ $$aI:(DE-He78)B310-20160331
000166506 980__ $$aUNRESTRICTED